Professor Hagan Bayley


Professor Bayley founded OxSyBio in 2014 and leads the ongoing development of the technology.

Educated at the University of Oxford, Professor Bayley spent most of his academic career at leading US academic institutions, including Harvard, MIT, the University of Massachusetts and Texas A&M University. He returned to the UK in 2003 as the Professor of Chemical Biology in the Department of Chemistry at the University of Oxford. Oxford’s Chemistry department is now the largest in the western world, and it has recently completed the construction of state-of-the-art facilities for multidisciplinary chemistry research. The academic standards of the department are regarded as second to none, and the teaching course was recently given the highest possible rankings by two educational authorities.

Professor Bayley’s research interests lie in the exploration of membrane protein structure and function, and the use of molecular engineering techniques that transform these proteins into unique measurement systems for exploring the chemistry of individual molecules. Professor Bayley founded Oxford NanoLabs (now Oxford Nanopore Technologies) in 2005, which is developing a new generation of nanopore-based electronic systems for the analysis of single molecules. Oxford Nanopore has raised in excess of £180m of funding, and in 2014 launched the MinION, a hand-held DNA sequencing device.


Dr Green


Dr Green joined OxSyBio with more than a decade of experience working with global pharmaceutical and diagnostics companies as well as biotech companies and goverments to drive the translation of science into next generation life-science businesses. This experience with Marakon Associates, Merck, GSK and Ernst & Young spans corporate and business unit strategy & transactions with a particular focus on personalised healthcare, clinical diagnostics, and small molecule and biological drug development. Hadrian graduated in Medicine and practiced across Australasia, the UK and several developing countries before earning a PhD in Molecular Imaging at the University of Cambridge in Molecular Imaging. Hadrian is a Fellow of the Cambridge Commonwealth Trust and was previously a bye-fellow of Queens’ College Cambridge.



Dr. Sam Olof


Dr. Olof is the Chief Business Development Officer at OxSyBio. He leads OxSyBio’s business development activities working to build strategic partnerships. Formerly the Chief Technical Officer at OxSyBio, Dr. Olof led OxSyBio’s technical activities in the 3D printing of artificial and synthetic tissues for diagnostic and therapeutic uses. He received a Masters Degree in Chemistry from Bristol University in 2009, and in 2013 a Ph.D, in Functional Nanomaterials, also at Bristol. His Ph.D work was supervised by Professor Stephen Mann FRS (Chemistry) and Professor Mervyn Miles FRS (Physics), and explored self-assembled artificial cells with advanced microscopy techniques. In 2013 he joined the Bayley Group to investigate the 3D printing of artificial tissues. This work has informed OxSyBio’s efforts in printed cell networks and has led to the submission of 2 patent applications and the raising of £1 m seed funding.




Dr David J. Lunn graduated in 2009 with an MSc in Chemistry from the University of Bristol, gaining industrial experience in 2008 working in the Netherlands for DSM Biomedical. David stayed at the University of Bristol to complete his PhD at the Bristol Chemical Synthesis Centre for Doctoral Training, under the supervision of Prof. Ian Manners FRS and Prof. Paul Pringle. In 2015, David was awarded a Marie Curie Global Research Fellowship to initiate an ongoing collaboration between Prof. Hagan Bayley FRS at the University of Oxford and Prof. Craig J. Hawker FRS at the Materials Research Laboratory, University of California, Santa Barbara, on the 3D-printing of responsive synthetic tissues. David’s technical experience is broad and interdisciplinary, covering synthetic chemistry, materials science and biotechnology. He has worked closely with a number of biotechnology start-ups and larger chemical companies and continues to collaborate with research groups, both in the UK and internationally, where his recent focus has been on the application of creative solutions for current industrial challenges.



Dr. Joan Gannon joined from the University of Oxford with over 14 years’ experience working with global pharmaceutical, biotechnology, diagnostic companies and academic institutions in both research and administrative roles. Joan received a B.Sc. in biotechnology and chemistry in 2005 and a Ph.D. in muscle biochemisty in 2009, both from Maynooth University, Ireland. Her Ph.D. research was on the pathobiochemistry of Sarcopenia (skeletal muscle ageing), and used various proteomic and mass spectrometry techniques to identify potential biomarkers for the disease. In 2009 she joined the laboratory of Drs Tommy Nilsson and John Bergeron, in the Research Institute of McGill University Health Centre, Montreal, Canada where she worked on the mechanisms of fatty liver disease using cell biological and proteomic methods. In 2012 Joan moved to the laboratory of Prof. Chris Schofield in the Organic Chemistry Dept. of the University of Oxford working on biochemical and cellular analyses of 2-oxoglutarate dependent oxygenases. Joan also collaborated with Prof. James McCullagh’s Mass Spectrometry Group also in the Organic Chemistry Dept. of the University of Oxford, on a project carrying out metabolomic studies of the role of IDH1 mutations in glioblastoma.





Dr Barker joined OxSyBio in 2017 as Head of Products coming from a global Biotechnology company. He has over a decade of experience in the development of commercial products and services from early concept through to market; these have spanned disciplines from infectious disease diagnostics to reference standards for genetic conditions. Recent roles included programming, design and fabrication of equipment and development of automated biology platforms within quality systems including ISO 9001, ISO 17025 and ISO 13485. Colin’s background is in molecular biology through a BSc in Genetics (University of Leicester) and a PhD in Toxicogenomics (MRC Toxicology Unit). Colin also has a formal post-graduate qualification in Leadership and Management and holds a professional membership of the Chartered Management Institute.